Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure

Analysis from the EVEREST trial

Nicolas Girerd, Peter Pang, Karl Swedberg, Angela Fought, Mary J. Kwasny, Haris Subacius, Marvin A. Konstam, Aldo Maggioni, Mihai Gheorghiade, Faiez Zannad

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Aims Post-discharge morbidity and mortality for acute heart failure (AHF) patients remains high. Although the adverse effects of neurohormonal activation are well known in chronic HF, the prognostic significance of serum aldosterone in patients hospitalized for AHF has not been well studied. Methods and results Asecondary analysis was carried out of the placebo arm (n = 1850) fromthe EVEREST trial which had aldosterone measured at baseline. All patientswere hospitalized for worsening HF and had an LVEF

Original languageEnglish (US)
Pages (from-to)1228-1235
Number of pages8
JournalEuropean Journal of Heart Failure
Volume15
Issue number11
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Aldosterone
Hospitalization
Heart Failure
Mortality
Serum
Placebos
Morbidity

Keywords

  • Acute heart failure
  • Aldosterone
  • Reduced ejection fraction
  • Survival

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure : Analysis from the EVEREST trial. / Girerd, Nicolas; Pang, Peter; Swedberg, Karl; Fought, Angela; Kwasny, Mary J.; Subacius, Haris; Konstam, Marvin A.; Maggioni, Aldo; Gheorghiade, Mihai; Zannad, Faiez.

In: European Journal of Heart Failure, Vol. 15, No. 11, 2013, p. 1228-1235.

Research output: Contribution to journalArticle

Girerd, Nicolas ; Pang, Peter ; Swedberg, Karl ; Fought, Angela ; Kwasny, Mary J. ; Subacius, Haris ; Konstam, Marvin A. ; Maggioni, Aldo ; Gheorghiade, Mihai ; Zannad, Faiez. / Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure : Analysis from the EVEREST trial. In: European Journal of Heart Failure. 2013 ; Vol. 15, No. 11. pp. 1228-1235.
@article{78f729c9bebf44fabb7526763c010d00,
title = "Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: Analysis from the EVEREST trial",
abstract = "Aims Post-discharge morbidity and mortality for acute heart failure (AHF) patients remains high. Although the adverse effects of neurohormonal activation are well known in chronic HF, the prognostic significance of serum aldosterone in patients hospitalized for AHF has not been well studied. Methods and results Asecondary analysis was carried out of the placebo arm (n = 1850) fromthe EVEREST trial which had aldosterone measured at baseline. All patientswere hospitalized for worsening HF and had an LVEF",
keywords = "Acute heart failure, Aldosterone, Reduced ejection fraction, Survival",
author = "Nicolas Girerd and Peter Pang and Karl Swedberg and Angela Fought and Kwasny, {Mary J.} and Haris Subacius and Konstam, {Marvin A.} and Aldo Maggioni and Mihai Gheorghiade and Faiez Zannad",
year = "2013",
doi = "10.1093/eurjhf/hft100",
language = "English (US)",
volume = "15",
pages = "1228--1235",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure

T2 - Analysis from the EVEREST trial

AU - Girerd, Nicolas

AU - Pang, Peter

AU - Swedberg, Karl

AU - Fought, Angela

AU - Kwasny, Mary J.

AU - Subacius, Haris

AU - Konstam, Marvin A.

AU - Maggioni, Aldo

AU - Gheorghiade, Mihai

AU - Zannad, Faiez

PY - 2013

Y1 - 2013

N2 - Aims Post-discharge morbidity and mortality for acute heart failure (AHF) patients remains high. Although the adverse effects of neurohormonal activation are well known in chronic HF, the prognostic significance of serum aldosterone in patients hospitalized for AHF has not been well studied. Methods and results Asecondary analysis was carried out of the placebo arm (n = 1850) fromthe EVEREST trial which had aldosterone measured at baseline. All patientswere hospitalized for worsening HF and had an LVEF

AB - Aims Post-discharge morbidity and mortality for acute heart failure (AHF) patients remains high. Although the adverse effects of neurohormonal activation are well known in chronic HF, the prognostic significance of serum aldosterone in patients hospitalized for AHF has not been well studied. Methods and results Asecondary analysis was carried out of the placebo arm (n = 1850) fromthe EVEREST trial which had aldosterone measured at baseline. All patientswere hospitalized for worsening HF and had an LVEF

KW - Acute heart failure

KW - Aldosterone

KW - Reduced ejection fraction

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84890091644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890091644&partnerID=8YFLogxK

U2 - 10.1093/eurjhf/hft100

DO - 10.1093/eurjhf/hft100

M3 - Article

VL - 15

SP - 1228

EP - 1235

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 11

ER -